A. Peter Kiener's Insider Trades & SAST Disclosures
A. Peter Kiener's most recent trade in LAVA Therapeutics NV was a trade of 33,390 Common Shares (Right to Buy) done . Disclosure was reported to the exchange on Feb. 13, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern A. Peter Kiener.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| LAVA Therapeutics NV | Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 33,390 | 33,390 | - | - | Common Shares (Right to Buy) | |
| Cue Biopharma Inc | Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | A. Peter Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 24,400 | 24,400 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 23 Mar 2023 | 9,682 | 9,682 (0%) | 0% | 2.9 | 27,691 | Common Stock |
| Cue Biopharma Inc | Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Mar 2023 | 9,682 | 96,062 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Peter A. Kiener | Director | Sale of securities on an exchange or to another person at price $ 3.28 per share. | 23 Mar 2023 | 9,325 | 357 (0%) | 0% | 3.3 | 30,586 | Common Stock |
| Cue Biopharma Inc | Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 15 Nov 2021 | 18,815 | 18,815 (0%) | 0% | 2.9 | 53,811 | Common Stock |
| Cue Biopharma Inc | Peter A. Kiener | Director | Sale of securities on an exchange or to another person at price $ 17.92 per share. | 15 Nov 2021 | 18,815 | 0 (0%) | 0% | 17.9 | 337,165 | Common Stock |
| Cue Biopharma Inc | Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 18,815 | 107,105 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.86 per share. | 15 Nov 2021 | 1,361 | 1,361 (0%) | 0% | 2.9 | 3,892 | Common Stock |
| Cue Biopharma Inc | Peter A. Kiener | Director | Sale of securities on an exchange or to another person at price $ 18.02 per share. | 15 Nov 2021 | 1,361 | 0 (0%) | 0% | 18.0 | 24,525 | Common Stock |
| Cue Biopharma Inc | Peter A. Kiener | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 1,361 | 105,744 | - | - | Stock Option (right to buy) | |
| Pieris Pharmaceuticals Inc | Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2021 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Cue Biopharma Inc | Peter A. Kiener | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Pieris Pharmaceuticals Inc | Peter A. Kiener | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jun 2020 | 40,000 | 40,000 | - | - | Stock Options (Right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges